Open Access

Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells

  • Authors:
    • Jie Liu
    • Yang Shu
    • Qingyu Zhang
    • Bin Liu
    • Juan Xia
    • Mingning Qiu
    • Huilai Miao
    • Mingyi Li
    • Runzhi Zhu
  • View Affiliations

  • Published online on: July 9, 2014     https://doi.org/10.3892/ol.2014.2330
  • Pages: 1645-1651
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) is a life‑threatening disease that is known to exhibit a poor prognosis. Therefore, it is important to identify an effective drug therapy for the treatment of HCC. Dihydromyricetin (DHM) is a flavonoid compound, isolated from the classical Chinese herb Ampelopsis grossedentata, which exhibits multiple pharmacological activities, including anticancer effects. In this study, the anticancer effect of DHM was investigated in nine different types of HCC cell lines via cell proliferation and immunoassays, as well as apoptosis detection. Two immortalized normal human liver cell lines were utilized to determine hepatotoxicity. The results revealed that DHM significantly inhibited cell proliferation and induced cell apoptosis in the HCC cell lines. However, DHM exhibited no cytotoxicity to normal human hepatic cell lines. Furthermore, it was found that DHM induced cell apoptosis in a p53‑dependent manner. DHM upregulated p53 expression, and the upregulation of p53 increased the levels of the cleaved caspase‑3 protein, directly inducing cell apoptosis. These results indicate that DHM is a promising candidate for the treatment of HCC.

References

1 

Chan SL and Yeo W: Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol. 27:862–872. 2012.

2 

Perz JF, Armstrong GL, Farrington LA, et al: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529–538. 2006.

3 

Takayama T, Sekine T, Makuuchi M, et al: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 356:802–807. 2000.

4 

Hu Y, Wang S, Wu X, et al: Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma. J Ethnopharmacol. 149:601–612. 2013.

5 

Chen YQ, Ni DJ, Cheng Q, et al: Study on the hypolipidemic effect of flavones and dihydromyricetin From Tengcha. J Tea Sci. 3:221–225. 2422007.

6 

Zhong ZX, Zhou GF, Chen XF and Qin JP: Experimental study on the protective effect of dihydromyricetin from Guangxi Ampelopsis grossepentata on liver. Chin J Tradit Med Sci Technol. 9:155–156. 2002.

7 

Xu JJ, Yao MJ and Wu MC: Study on biological efficacy of dihydromyricetin. Food Sci. 29:622–625. 2008.

8 

Shen Y, Lindemeyer AK, Gonzalez C, et al: Dihydromyricetin as a novel anti-alcohol intoxication medication. J Neurosci. 32:390–401. 2012.

9 

He GX, Yang WL, Pei G, et al: Studies on the effect of dihydromyricetin on antilipid-peroxidation. Zhongguo Zhong Yao Za Zhi. 28:1188–1190. 2003.(In Chinese).

10 

Mu R, Lu N, Wang J, et al: An oxidative analogue of gambogic acid-induced apoptosis of human hepatocellular carcinoma cell line HepG2 is involved in its anticancer activity in vitro. Eur J Cancer Prev. 19:61–67. 2010.

11 

Alenzi FQ, Alenazi BQ, AL-Anazy FH, et al: The role of caspase activation and mitochondrial depolarisation in cultured human apoptotic eosinophils. Saudi J Biol Sci. 17:29–36. 2010.

12 

Wolf BB, Schuler M, Echeverri F and Green DR: Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem. 274:30651–30656. 1999.

13 

Fan TJ, Han LH, Cong RS and Liang J: Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai). 37:719–727. 2005.

14 

Ling Y, Lu N, Gao Y, et al: Endostar induces apoptotic effects in HUVECs through activation of caspase-3 and decrease of Bcl-2. Anticancer Res. 29:411–417. 2009.

15 

Cheng EHY, Wei MC, Weiler S, et al: BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell. 8:705–711. 2001.

16 

Hussein MR: Analysis of p53, BCL-2 and epidermal growth factor receptor protein expression in the partial and complete hydatidiform moles. Exp Mol Pathol. 87:63–69. 2009.

17 

Degenhardt K, Chen G, Lindsten T and White E: BAX and BAK mediate p53-independent suppression of tumorigenesis. Cancer Cell. 2:193–203. 2002.

18 

Henry H, Thomas A, Shen Y and White E: Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene. 21:748–760. 2002.

Related Articles

Journal Cover

October 2014
Volume 8 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, J., Shu, Y., Zhang, Q., Liu, B., Xia, J., Qiu, M. ... Zhu, R. (2014). Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells. Oncology Letters, 8, 1645-1651. https://doi.org/10.3892/ol.2014.2330
MLA
Liu, J., Shu, Y., Zhang, Q., Liu, B., Xia, J., Qiu, M., Miao, H., Li, M., Zhu, R."Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells". Oncology Letters 8.4 (2014): 1645-1651.
Chicago
Liu, J., Shu, Y., Zhang, Q., Liu, B., Xia, J., Qiu, M., Miao, H., Li, M., Zhu, R."Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells". Oncology Letters 8, no. 4 (2014): 1645-1651. https://doi.org/10.3892/ol.2014.2330